Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT02975492
Other study ID # RECHMPL15_0500
Secondary ID UF 9676
Status Recruiting
Phase N/A
First received
Last updated
Start date December 14, 2017
Est. completion date December 2024

Study information

Verified date April 2023
Source University Hospital, Montpellier
Contact Denis MORIN, MD
Phone 0467336607
Email d-morin@chu-montpellier.fr
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Recommendations for vitamin D supplementation for subjets between 2 and 18 years offer strong sequential doses of vitamin D: 2 times 100 000 units in spaced winter period of 3 months. Data from the literature show a further increase in the incidence of oxalo-calcium stones in children and adolescents associated with hypercalciuria with training Randall plates, essential step lithogenesis calcium oxalate. Knowing the links between vitamin D and urinary calcium excretion, these data lead to the question of increased sensitivity in some children with vitamin D, sensitivity could explain these situations with hypercalciuria increase the gallstone risk. This increased sensitivity to vitamin D may unmask particularly if inputs of high doses of vitamin responsible then a transient hypercalciuria with development of microcrystals.


Recruitment information / eligibility

Status Recruiting
Enrollment 280
Est. completion date December 2024
Est. primary completion date May 2024
Accepts healthy volunteers No
Gender All
Age group 2 Years to 18 Years
Eligibility Inclusion Criteria: - Children aged 2 to 17 years included - Obtaining informed consent of the parents signed - Participants aged 18 years included

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Cholecalciferol sequential dose
sequential dose administration of the treatment
Cholecalciferol daily dose
daily dose administration of the treatment

Locations

Country Name City State
France Pediatric department Montpellier
France Pediatric department Nîmes

Sponsors (1)

Lead Sponsor Collaborator
University Hospital, Montpellier

Country where clinical trial is conducted

France, 

Outcome

Type Measure Description Time frame Safety issue
Primary Changes from calcium level in urines at day 7, day 14 and day 28 day 7, day 14 and day 28